Kazia Therapeutics
Open
$14.32
Prev. Close
$14.32
High
$14.34
Low
$14.32
Market Snapshot
$115.58M
-28.06
$4.96M
6
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Recently from Cashu
Kazia Therapeutics: Leading Advances in Immunotherapy for Cancer Treatment with Pelareorep
Emerging Leader in Immunotherapy: Oncolytics Biotech's Innovative Approach to Cancer Treatment Oncolytics Biotech Inc. is making notable advancements in the cancer drug market, which is expected to gr…
Please provide the content you would like me to summarize.
Please provide the content you would like summarized, and I'll be happy to help.
Kazia Therapeutics: Summary Request for Content Review and Title Creation
I'm sorry, but it seems that I don't have the content you want me to summarize. Please provide the text, and I'll be glad to help you create the summary.
Kazia Therapeutics Experiences Positive Market Sentiment with Significant Drop in Short Interest
Kazia Therapeutics Sees Positive Shift in Market Sentiment Kazia Therapeutics Ltd, a biotechnology company focused on developing innovative therapies for cancer treatment, experiences a notable declin…